C-Rad AB Class B (CRAD.B) Price & Analysis

Compare

0 Followers

CRAD.B Stock Chart & Stats

kr31.90

-kr0.15(-0.47%)

At close: Mar 06 4:00 PM EST

kr31.90

-kr0.15(-0.47%)

Day’s Range― - ―

52-Week Rangekr25.30 - kr37.40

Previous CloseN/A

Volume2.26K

Average Volume (3M)58.03K

Market Cap

kr943.79M

Enterprise Valuekr750.27M

Total Cash (Recent Filing)kr171.20M

Total Debt (Recent Filing)kr18.80M

Price to Earnings (P/E)89.6

Beta0.49

Next Earnings

May 06, 2026

EPS Estimate

0.46

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.20

Shares Outstanding32,904,050

10 Day Avg. Volume15,927

30 Day Avg. Volume58,029

Financial Highlights & Ratios

PEG Ratio-1.27

Price to Book (P/B)3.12

Price to Sales (P/S)2.45

P/FCF Ratio15.22

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Conservative Balance SheetC‑Rad’s very low debt-to-equity and rising equity base provide durable financial flexibility. Low leverage reduces refinancing and interest risks, enabling sustained investment in R&D, service infrastructure and selective M&A without stressing cash flow during cyclical downturns.

High Gross MarginsSustained gross margins near the mid‑60s indicate strong product economics and pricing power in SGRT systems. High gross profitability supports reinvestment, resilience to cost inflation and the potential to expand recurring software/service margins over time.

Improved Cash Generation (2025)Material improvement in operating and free cash flow in 2025 shows the business can convert earnings into liquidity. Reliable cash generation funds service networks, software development and working capital needs, underpinning long‑term sustainability of recurring revenue.

Bears Say

Profitability Reset In 2025A sharp net margin contraction and revenue decline in 2025 indicates structural pressure on operating leverage or mix shifts. If persistent, lower margins will reduce cash available for R&D and services, and make earnings more sensitive to volume volatility over coming quarters.

Negative Revenue And EPS TrendsMulti‑period declines in revenue and severe EPS contraction highlight demand or execution issues. Continued negative top‑line and EPS trends reduce visibility into sustainable growth, hinder reinvestment capacity, and raise questions about the consistency of recurring revenue expansion.

Uneven Cash Flow HistoryVolatile free cash flow history increases financing and timing risk for capex and service rollouts. Irregular cash conversion can force opportunistic capital raises or constrain long‑term investments, weakening competitive positioning in a capital‑intensive medical device market.

C-Rad AB Class B News

C-RAD’s New CEO Targets Sharper Execution After Profit Slump in 2025

C-Rad AB Class B ( ($SE:CRAD.B) ) has shared an update. C-RAD reported a weaker fourth quarter and...

12d ago

C-RAD Schedules Year-End 2025 Results Presentation for 12 February

C-Rad AB Class B ( ($SE:CRAD.B) ) has provided an announcement. C-RAD AB announced that it will publish...

26d ago

C-RAD Names Former Biotage Chief Tomas Blomquist as CEO to Drive Next Growth Phase

C-Rad AB Class B ( ($SE:CRAD.B) ) has provided an update. C-RAD has appointed Tomas Blomquist as its...

28d ago

C-RAD AB Announces Share Repurchase Program to Optimize Capital Structure

C-Rad AB Class B ( ($SE:CRAD.B) ) has provided an update. C-RAD AB has announced a decision to...

4M ago

C-RAD AB Reports Strong Q3 2025 Earnings and Strategic Growth Initiatives

C-Rad AB Class B ( ($SE:CRAD.B) ) just unveiled an update. C-RAD AB reported a positive earnings trend...

4M ago

C-RAD Announces Leadership Transition with New Acting CEO

C-Rad AB Class B ( ($SE:CRAD.B) ) has issued an update. C-RAD has announced a leadership change with...

4M ago

C-RAD Expedites Q3 2025 Interim Report Approval

An announcement from C-Rad AB Class B ( ($SE:CRAD.B) ) is now available. C-RAD has announced an advancement...

4M ago

24C Earnings this Week: How Will it Perform?

C-Rad AB Class B (24C) is scheduled to report 3rd quarter earnings on 10/23/2025, before the market opens....

4M ago

C-RAD to Present Q3 2025 Interim Report

C-Rad AB Class B ( ($SE:CRAD.B) ) has issued an announcement. C-RAD AB announced it will release its...

5M ago

C-RAD Expands Czech Market Presence with Key Hospital Order

C-Rad AB Class B ( ($SE:CRAD.B) ) has provided an update. C-RAD has secured a significant order from...

5M ago

CRAD.B FAQ

What was C-Rad AB Class B’s price range in the past 12 months?

C-Rad AB Class B lowest stock price was kr25.30 and its highest was kr37.40 in the past 12 months.

What is C-Rad AB Class B’s market cap?

C-Rad AB Class B’s market cap is kr943.79M.

When is C-Rad AB Class B’s upcoming earnings report date?

C-Rad AB Class B’s upcoming earnings report date is May 06, 2026 which is in 72 days.

How were C-Rad AB Class B’s earnings last quarter?

C-Rad AB Class B released its earnings results on Feb 12, 2026. The company reported kr0.2 earnings per share for the quarter, missing the consensus estimate of kr0.668 by -kr0.468.

Is C-Rad AB Class B overvalued?

According to Wall Street analysts C-Rad AB Class B’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does C-Rad AB Class B pay dividends?

C-Rad AB Class B does not currently pay dividends.

What is C-Rad AB Class B’s EPS estimate?

C-Rad AB Class B’s EPS estimate is 0.46.

How many shares outstanding does C-Rad AB Class B have?

C-Rad AB Class B has 32,904,050 shares outstanding.

What happened to C-Rad AB Class B’s price movement after its last earnings report?

C-Rad AB Class B reported an EPS of kr0.2 in its last earnings report, missing expectations of kr0.668. Following the earnings report the stock price went down -10.159%.

Which hedge fund is a major shareholder of C-Rad AB Class B?

Currently, no hedge funds are holding shares in SE:CRAD.B

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

C-Rad AB Class B

C-Rad AB (publ), together with its subsidiaries, develops, manufactures, and sells systems with applications in radiation therapy for the treatment of cancer worldwide. The company operates through two segments, Positioning and Imaging. Its products include Sentinel 4D CT, a laser-based optical surface scanning system; Catalyst, a 4D surface image guided radiation therapy (SIGRT) solution; Catalyst HD, an SIGRT solution on stereotactic radiation therapy for online patient tracking before and during treatment delivery; Catalyst+, an SIGRT solution for high precision patient positioning, intra-fraction motion management, and respiratory gating; and Catalyst+ HD, a solution for high precision patient positioning, intra-fraction motion management, and respiratory gating for conventional and stereotactic treatment delivery. The company's products also comprise Catalyst Tomo, an enhanced positioning solution for tomotherapy; Catalyst PT, a real-time tracking solution for particle therapy; Cyrpa laser positioning products; cAccessory, which automates the registration and validation of treatment accessories; and cPatient that automates patient identity validation without the need for contact between patients and devices. In addition, it offers installation, application training, and aftersales services. C-Rad AB (publ) was founded in 2004 and is headquartered in Uppsala, Sweden.